Leerink Partnrs Forecasts Increased Earnings for REGENXBIO

REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Stock analysts at Leerink Partnrs increased their FY2028 earnings per share (EPS) estimates for shares of REGENXBIO in a note issued to investors on Thursday, July 17th. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will post earnings of ($2.58) per share for the year, up from their prior forecast of ($2.59). The consensus estimate for REGENXBIO's current full-year earnings is ($4.84) per share.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its earnings results on Monday, May 12th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.41 by ($0.29). The business had revenue of $89.01 million for the quarter, compared to the consensus estimate of $105.35 million. REGENXBIO had a negative net margin of 100.62% and a negative return on equity of 53.29%.

Several other brokerages also recently issued reports on RGNX. The Goldman Sachs Group decreased their target price on REGENXBIO from $14.00 to $12.00 and set a "neutral" rating on the stock in a research note on Thursday, April 17th. Chardan Capital reissued a "buy" rating and set a $52.00 target price on shares of REGENXBIO in a research note on Monday, June 9th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $31.63.

REGENXBIO Trading Up 0.4%

RGNX traded up $0.04 on Monday, hitting $9.13. 554,523 shares of the company's stock traded hands, compared to its average volume of 575,785. The company's 50 day simple moving average is $9.00 and its 200-day simple moving average is $7.97. The firm has a market cap of $457.96 million, a price-to-earnings ratio of -2.94 and a beta of 1.06. REGENXBIO has a one year low of $5.03 and a one year high of $15.36.

Institutional Trading of REGENXBIO

Large investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its stake in REGENXBIO by 67.0% in the 4th quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company's stock worth $31,975,000 after acquiring an additional 1,659,206 shares during the last quarter. Janney Montgomery Scott LLC bought a new position in shares of REGENXBIO during the 1st quarter valued at approximately $484,000. Wealth Enhancement Advisory Services LLC bought a new position in shares of REGENXBIO during the 1st quarter valued at approximately $123,000. Price T Rowe Associates Inc. MD increased its position in shares of REGENXBIO by 9.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,910 shares of the biotechnology company's stock valued at $185,000 after purchasing an additional 1,982 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its position in shares of REGENXBIO by 370.1% during the 4th quarter. BNP Paribas Financial Markets now owns 96,093 shares of the biotechnology company's stock valued at $743,000 after purchasing an additional 75,652 shares during the last quarter. Institutional investors own 88.08% of the company's stock.

Insider Transactions at REGENXBIO

In other REGENXBIO news, Director Kenneth T. Mills sold 20,602 shares of REGENXBIO stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $7.91, for a total value of $162,961.82. Following the sale, the director owned 475,103 shares of the company's stock, valued at $3,758,064.73. The trade was a 4.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 12.79% of the stock is currently owned by insiders.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.